0001157523-12-002159.txt : 20120426 0001157523-12-002159.hdr.sgml : 20120426 20120426160027 ACCESSION NUMBER: 0001157523-12-002159 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20120426 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20120426 DATE AS OF CHANGE: 20120426 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VCA ANTECH INC CENTRAL INDEX KEY: 0000817366 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE SERVICES [0700] IRS NUMBER: 954097995 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16783 FILM NUMBER: 12783484 BUSINESS ADDRESS: STREET 1: 12401 WEST OLYMPIC BOULEVARD CITY: LOS ANGELES STATE: CA ZIP: 90064-1022 BUSINESS PHONE: (310) 571-6500 MAIL ADDRESS: STREET 1: 12401 WEST OLYMPIC BOULEVARD CITY: LOS ANGELES STATE: CA ZIP: 90064-1022 FORMER COMPANY: FORMER CONFORMED NAME: VETERINARY CENTERS OF AMERICA INC DATE OF NAME CHANGE: 19940328 8-K 1 a50253959.htm VCA ANTECH, INC. 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
______________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): April 26, 2012

VCA Antech, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware

001-16783

95-4097995

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

12401 West Olympic Boulevard
Los Angeles, California 90064-1022

(Address of Principal Executive Offices)

(310) 571-6500
(Registrant’s Telephone Number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



1

Item 2.02:  Results of Operations and Financial Condition

On April 26, 2012, VCA Antech, Inc. issued a press release which included earnings for the first quarter of fiscal year 2012. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

Item 9.01: Financial Statements, Pro Forma Financial Information and Exhibits

(c)  Exhibits

 

99.1

Press release dated April 26, 2012, regarding earnings for the first quarter of fiscal year 2012.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

April 26, 2012

VCA Antech, Inc.

 
 

 

/s/ Tomas W. Fuller

By:

Tomas W. Fuller

Its:

Chief Financial Officer

3

EXHIBIT INDEX

Exhibits

 
 

99.1

Press release dated April 26, 2012, regarding earnings for the first quarter of fiscal year 2012.






4

EX-99.1 2 a50253959ex99_1.htm EXHIBIT 99.1

Exhibit 99.1

VCA Antech, Inc. Reports First Quarter 2012 Results

  • First quarter revenue increased 15.3% to a first quarter record of $409.5 million
  • First quarter gross profit increased 17% to $93.4 million
  • First quarter diluted earnings per common share of $0.40
  • First quarter adjusted diluted earnings per common share of $0.34

LOS ANGELES--(BUSINESS WIRE)--April 26, 2012--VCA Antech, Inc. (NASDAQ:WOOF), a leading animal healthcare company in the United States and Canada, today reported financial results for the first quarter ended March 31, 2012 as follows: revenue increased 15.3% to a first quarter record of $409.5 million; gross profit increased 17% to $93.4 million; net income was $35.2 million and diluted earnings per common share was $0.40.

The first quarter of 2012 included a gain of $5.7 million on our 20% interest in Associate Veterinary Clinics (“AVC”) held at the time we became the sole non-veterinarian shareholder of AVC. Excluding the gain, adjusted diluted earnings per common share was $0.34.

Bob Antin, Chairman and CEO, stated, “I am extremely pleased with our results for the quarter. This is the third consecutive quarter of improved organic revenue growth in both our Animal Hospital and Laboratory segments. In addition, we experienced margin expansion in each of these segments. Given these positive results, we remain optimistic with respect to our outlook for 2012.

“Animal Hospital revenue in the first quarter of 2012 increased 17.1% to $316.1 million driven by acquisitions made in the past twelve months and same-store revenue growth of 3.5%. Our Animal Hospital gross margin decreased slightly to 14.4%, compared to 14.7%, for the prior year quarter, and our Animal Hospital operating margin declined to 12.0%, compared to 12.4%, for the prior-year quarter. Our same-store gross profit margin increased to 14.9%, from 14.8%. During the quarter, we increased our investment in AVC which had historical annual revenue of $96.0 million. We also acquired nine independent animal hospitals which had historical combined annual revenue of $12.2 million.

“Laboratory revenue in the first quarter increased 6.5% to $84.7 million driven by both an increase in the number of requisitions and the average revenue per requisition. Our Laboratory gross profit margin increased by 1.7% to 47.9% and our operating margin increased 1.1% to 38.9%.

“Revenue from our other operations reported in our All Other segment increased $7.2 million in the first quarter to $26.3 million, which related primarily to the acquisition of Vetstreet in August 2011.”

Conference Call

We will discuss our first quarter 2012 financial results during a conference call today, April 26th, at 4:30 p.m. Eastern Time. A live broadcast of the call may be accessed by visiting our website at http://investor.vcaantech.com. The call may also be accessed by dialing (877) 293-5492. Interested parties should call at least ten minutes prior to the start of the call to register. Replay of the webcast will be available for ninety days by visiting the company’s website.


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Among the forward looking statements is our statement of optimism about our outlook for 2012 and other statements in this press release addressing our plans, expectations, future financial position and results of operation. These forward-looking statements are not historical facts and are inherently uncertain and out of our control. Any or all of our forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Actual future results may vary materially. Among other factors that could cause our actual results to differ from this forward-looking information are: the continued effects of the economic uncertainty prevailing in regions in which we operate; our ability to execute on our growth strategy and to manage acquired operations (including Vetstreet); changes in demand for our products and services; fluctuations in our revenue adversely affecting our gross profit, operating income and margins; and the effects of the other factors discussed in our Annual Report on Form 10-K, Reports on Form 10-Q and our other filings with the SEC.

About VCA Antech

We own, operate and manage the largest networks of freestanding veterinary hospitals and veterinary-exclusive clinical laboratories in the country and we provide the largest online communication, professional education and marketing solution to the veterinary community. We also supply diagnostic imaging equipment to the veterinary industry.


 

VCA Antech, Inc.

Consolidated Income Statements
(Unaudited)
(In thousands, except per share amounts)
 
      Three Months Ended
March 31,
2012       2011
Revenue:
Animal hospital $ 316,125 $ 269,941
Laboratory 84,730 79,549
All other 26,325 19,096
Intercompany   (17,715 )   (13,463 )
  409,465     355,123  
 
Direct costs 316,086 275,345
 
Gross profit:
Animal hospital 45,556 39,553
Laboratory 40,551 36,730
All other 8,667 4,458
Intercompany   (1,395 )   (963 )
  93,379     79,778  
 
Selling, general and administrative expense:
Animal hospital 7,057 6,083
Laboratory 7,598 6,636
All other 9,283 3,556
Corporate   15,113     9,908  
  39,051     26,183  
 
Loss on sale and disposal of assets   523     89  
 
Operating income 53,805 53,506
 
Interest expense, net 4,087 4,548
Business combination adjustment gain (5,719 ) -
Other (income) expense   (207 )   58  
Income before provision for
income taxes 55,644 48,900
Provision for income taxes   19,323     18,933  
Net income   36,321     29,967  
Net income attributable to noncontrolling interests   1,076     1,128  
Net income attributable to VCA Antech, Inc. $ 35,245   $ 28,839  
 
Diluted earnings per share $ 0.40   $ 0.33  
Shares used for computing diluted
earnings per share   88,055     87,245  
 

 

VCA Antech, Inc.

Consolidated Balance Sheets
(Unaudited)
(In thousands)
 
      March 31,       December 31,
2012 2011
Assets
 
Current assets:
Cash and cash equivalents $ 72,716 $ 63,651
Trade accounts receivable, net 63,849 58,279
Inventory 52,697 48,661
Prepaid expenses and other 24,091 21,883
Deferred income taxes 26,854 26,310
Prepaid income taxes   6,087   18,373
Total current assets 246,294 237,157
Property and equipment, net 377,082 370,646
Other assets:
Goodwill 1,338,569 1,237,607
Other intangible assets, net 112,285 92,403
Deferred financing costs, net 5,188 5,435
Other   50,173   52,120
Total assets $ 2,129,591 $ 1,995,368
 
Liabilities and Equity
 
Current liabilities:
Current portion of long-term debt $ 34,920 $ 32,571
Accounts payable 40,136 37,797
Accrued payroll and related liabilities 55,829 42,658
Other accrued liabilities   54,402   43,968
Total current liabilities 185,287 156,994
Long-term debt, less current portion 621,898 586,282
Deferred income taxes 109,361 101,229
Other liabilities 34,800 25,947
Redeemable noncontrolling interest 6,950 6,964
VCA Antech, Inc. stockholders' equity:
Common stock 87 87
Additional paid-in capital 378,609 361,715
Accumulated earnings 780,903 745,658
Accumulated other comprehensive income   1,482   418
Total VCA Antech, Inc. stockholders' equity 1,161,081 1,107,878
Noncontrolling interest   10,214   10,074
Total equity   1,171,295   1,117,952
Total liabilities and equity $ 2,129,591 $ 1,995,368
 

 
VCA Antech, Inc.
Consolidated Statements of Cash Flows
(Unaudited)
(In thousands)
 
      Three Months Ended
March 31,
2012       2011
Cash flows from operating activities:
Net income $ 36,321 $ 29,967
Adjustments to reconcile net income to net cash provided by
operating activities:
Depreciation and amortization 16,562 13,380
Amortization of debt costs 322 388
Provision for uncollectible accounts 1,146 1,297
Business combination adjustment gain (5,719 ) -
Loss on sale and disposal of assets 523 89
Share-based compensation 4,183 1,068
Deferred income taxes 4,212 8,035
Excess tax benefit from exercise of stock options (187 ) (185 )
Other (391 ) 171
Changes in operating assets and liabilities:
Accounts receivable (4,606 ) (6,933 )
Inventory, prepaid expenses and other assets (2,939 ) 1,417
Income taxes 12,698 9,922
Accounts payable and other accrued liabilities 814 (8,120 )
Accrued payroll and related liabilities   10,725     10,734  
Net cash provided by operating activities   73,664     61,230  
Cash flows from investing activities:
Business acquisitions, net of cash acquired (65,472 ) (5,467 )
Real estate acquired in connection with business acquisitions - (1,200 )
Property and equipment additions (16,072 ) (12,034 )
Proceeds from sale of assets 36 22
Other   193     (131 )
Net cash used in investing activities   (81,315 )   (18,810 )
Cash flows from financing activities:
Repayment of long-term obligations (34,626 ) (7,301 )
Proceeds from the issuance of long-term obligations 50,000 -
Borrowings on revolving credit facility 50,000 -
Repayments on revolving credit facility (50,000 ) -
Payment of financing costs (101 ) -
Distributions to noncontrolling interest partners (719 ) (652 )
Proceeds from issuance of common stock under stock option plans 2,621 1,175
Repurchase of common stock (579 ) (2,337 )
Excess tax benefit from exercise of stock options 187 185
Other   (151 )   (345 )
Net cash provided by (used in) financing activities   16,632     (9,275 )
Effect of currency exchange rate changes on cash and cash equivalents 84 128
Decrease in cash and cash equivalents 9,065 33,273
Cash and cash equivalents at beginning of period   63,651     97,126  
Cash and cash equivalents at end of period $ 72,716   $ 130,399  
 

 
VCA Antech, Inc.
Supplemental Operating Data
(Unaudited - In thousands, except per share amounts)
 
Table #1            
Reconciliation of net income attributable to Three Months Ended
VCA Antech, Inc., to adjusted net income March 31,
attributable to VCA Antech, Inc. (1) 2012 2011
 
Net income attributable to VCA Antech, Inc. $ 35,245 $ 28,839
Business combination adjustment gain (2)   (5,719 )   -
Adjusted net income attributable to VCA Antech, Inc. $ 29,526   $ 28,839
 
Table #2 Three Months Ended
Reconciliation of diluted earnings per share to March 31,
adjusted diluted earnings per share (1) 2012 2011
 
Diluted earnings per share $ 0.40 $ 0.33
Impact of business combination adjustment gain (2)   (0.06 )   -
Adjusted diluted earnings per share $ 0.34   $ 0.33
Shares used for computing adjusted

diluted earnings per share

  88,055     87,245
 

(1) Management uses adjusted net income and adjusted diluted earnings per share, and its components among other factors, to measure the performance of the overall Company.  Further, we believe that investors’ understanding of our performance is enhanced by disclosing these measures. Adjusted net income and its components and adjusted diluted EPS measures are not, and should not be viewed as substitutes for, U.S. generally accepted accounting principles (GAAP) net income and its components and diluted earnings per share.

(2) As a result of the acquisition of a controlling interest in AVC, we recorded a gain for the increase in value of our previously held interest in AVC, which we acquired in 2008.

 

 

VCA Antech, Inc.

Supplemental Operating Data
(Unaudited - In thousands)
 
      As of
Table #3 March 31,         December 31,
Selected consolidated balance sheet data 2012 2011
 
Debt:
Senior term notes $ 616,094 $ 573,984
Other debt and capital leases   40,724     44,869  
Total debt $ 656,818   $ 618,853  
 
Three Months Ended
Table #4 March 31,
Selected expense data   2012     2011  
 
Rent expense $ 16,045   $ 13,271  
 
Depreciation and amortization included
in direct costs:
Animal hospital $ 11,226 $ 9,799
Laboratory 2,468 2,369
All other 1,502 410
Intercompany   (362 )   (301 )
14,834 12,277
Depreciation and amortization included in selling, general and
administrative expense   1,728     1,103  
Total depreciation and amortization $ 16,562   $ 13,380  
 
Share-based compensation included in direct costs:

Laboratory

$ 123 $ 78
 
Share-based compensation included in
selling, general and administrative expense:
Animal hospital 341 218
Laboratory 385 240
All other 152 55
Corporate   3,182     477  
  4,060     990  
Total share-based compensation $ 4,183   $ 1,068  

CONTACT:
VCA Antech, Inc.
Tomas Fuller
Chief Financial Officer
310-571-6505